Meanwhile, Lilly also confirmed that it will start running a head-to-head cardiovascular outcomes trial for Trulicity and one of its pipeline diabetes candidates – dual GIP/GLP1 agonist ...

The SUMMIT trial compared the safety and efficacy of tirzepatide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Results from the trial concluded that treatment ...

Overweight and obesity are common in patients with heterozygous familial hypercholesterolemia (HeFH) and are associated with a greater risk of atherosclerotic cardiovascular disease (ASCVD) starting ...